# Phase 3 syndrome trials recruiting: 128 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 128 trials in phase 3 for syndrome that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 syndrome trials: 128 rows for $6.40, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/syndrome

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 128
- Recruiting or not yet: 128
- Read on: November 19, 2026

## Trials

The 25 newest of 128, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07934225 | Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes | Fayoum University | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2, Insulin Resistance Syndrome | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934225) |
| November 4, 2026 | NCT07916259 | The Study of Brave-LC LDN Treatment Trial | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Not yet recruiting | Post-acute COVID-19 Syndrome | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916259) |
| October 30, 2026 | NCT07908082 | Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Phase 3 | Not yet recruiting | Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS), Ishemic and Thrombotic Complications | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908082) |
| October 15, 2026 | NCT07875153 | Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome | Assistance Publique - Hôpitaux de Paris | Phase 3 | Not yet recruiting | Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome, Thrombosis | 234 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875153) |
| September 14, 2026 | NCT07817186 | Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT | Carelon Research | Phase 3 | Not yet recruiting | HCM, Noonan Syndrome and Other Rasopathy, Heart Failure (Pediatric) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817186) |
| September 8, 2026 | NCT07806279 | Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk | Uppsala University | Phase 3 | Not yet recruiting | Cardiometabolic Syndrome, Obesity and Cardiovascular Risk, Overweight , Obesity | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806279) |
| August 27, 2026 | NCT07791199 | Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers | Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis, Psoriatic Arthritis | 2,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791199) |
| August 26, 2026 | NCT07786662 | Early Corticosteroids in Severe Influenza Pneumonia | Centre Hospitalier Régional Metz-Thionville | Phase 3 | Not yet recruiting | Severe Influenza, Intensive Care (ICU), Reanimation, Infectious Diseases, Hygiene | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786662) |
| August 24, 2026 | NCT07782827 | CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS) | Ionis Pharmaceuticals, Inc. | Phase 3 | Recruiting | Angelman Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782827) |
| August 18, 2026 | NCT07771439 | A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older... | Sanofi | Phase 3 | Recruiting | Chronic Graft Versus Host Disease | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771439) |
| August 18, 2026 | NCT07770282 | Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome | All India Institute of Medical Sciences, Bhubaneswar | Phase 3 | Not yet recruiting | Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin Resistance | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770282) |
| August 14, 2026 | NCT07765914 | Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome | Children's Hospital of Fudan University | Phase 3 | Not yet recruiting | Nephrotic Syndrome | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765914) |
| August 3, 2026 | NCT07742735 | A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome... | VectivBio AG | Phase 3 | Recruiting | Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF) | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07742735) |
| July 30, 2026 | NCT07736313 | Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients | Assiut University | Phase 3 | Not yet recruiting | Acute Coronary Syndromes | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736313) |
| June 22, 2026 | NCT07658976 | Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy | HIV Prevention Trials Network | Phase 3 | Not yet recruiting | HIV Infection, Sexually Transmitted Infection | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658976) |
| June 2, 2026 | NCT07621809 | Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease... | Novartis Pharmaceuticals | Phase 3 | Recruiting | Sjögren´s Disease | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621809) |
| May 29, 2026 | NCT07614152 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Recruiting | Turner Syndrome | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614152) |
| May 26, 2026 | NCT07605429 | BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. | OHB Pediatrics Ltd. | Phase 3 | Recruiting | Angelman Syndrome | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07605429) |
| May 22, 2026 | NCT07604103 | Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute... | University of Brawijaya | Phase 3 | Recruiting | Acute Coronary Syndromes (ACS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604103) |
| May 18, 2026 | NCT07593391 | An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome | Neuren Pharmaceuticals Limited | Phase 3 | Recruiting | Phelan-McDermid Syndrome | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593391) |
| May 13, 2026 | NCT07582835 | Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty. | Cardiocentro Ticino | Phase 3 | Recruiting | Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndromes, Antiplatelet Therapy, Single... | 355 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582835) |
| May 8, 2026 | NCT07576660 | Dexamethasone Treatment for Sepsis-associated Acute Respiratory Distress Syndrome: a Multicenter, Randomised, Double-blinded, Controlled... | Southeast University, China | Phase 3 | Recruiting | Acute Respiratory Distress Syndrome (ARDS) | 1,704 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576660) |
| April 27, 2026 | NCT07552987 | A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome | Kedrion S.p.A. | Phase 3 | Not yet recruiting | Stiff Person Syndrome | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552987) |
| April 15, 2026 | NCT07530640 | Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities | Children's Hospital of Fudan University | Phase 3 | Recruiting | Kawasaki Disease, Coronary Artery Abnormalities | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530640) |
| April 14, 2026 | NCT07528196 | Study of Xuanbai Shengmai Decoction in the Treatment of Acute Respiratory Distress Syndrome | Southeast University, China | Phase 3 | Not yet recruiting | Acute Respiratory Distress Syndrome (ARDS) | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528196) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Assistance Publique - Hôpitaux de Paris | 10 |
| University of Colorado, Denver | 3 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 3 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| Children's Hospital of Fudan University | 3 |
| Neuren Pharmaceuticals Limited | 2 |
| Ottawa Hospital Research Institute | 2 |
| Universitair Ziekenhuis Brussel | 2 |
| Southeast University, China | 2 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 2 |
| Breathe Biologics, Inc. | 1 |
| University Hospital, Strasbourg, France | 1 |
| University of California, San Diego | 1 |
| All India Institute of Medical Sciences, Bhubaneswar | 1 |
| ONY | 1 |
| [Ionis Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/ionis-pharmaceuticals-inc) | 1 |
| Vor Biopharma | 1 |
| [Xiamen Amoytop Biotech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/xiamen-amoytop-biotech-co-ltd) | 1 |
| National University Hospital, Singapore | 1 |
| Nantes University Hospital | 1 |
| Mahidol University | 1 |
| ShangHai Ji Ai Genetics & IVF Institute | 1 |
| University Hospital, Lille | 1 |
| Xiyuan Hospital of China Academy of Chinese Medical Sciences | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 46 |
| France | 35 |
| Spain | 23 |
| Italy | 21 |
| China | 18 |
| Canada | 17 |
| United Kingdom | 16 |
| Germany | 14 |
| Poland | 11 |
| Belgium | 11 |
| Turkey (Türkiye) | 10 |
| Netherlands | 10 |
| Israel | 10 |
| Australia | 9 |
| Brazil | 9 |
| Hungary | 9 |
| South Korea | 9 |
| Denmark | 9 |
| India | 8 |
| Japan | 8 |
| Argentina | 8 |
| Taiwan | 7 |
| Romania | 7 |
| Switzerland | 6 |
| Greece | 6 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Records storage companies in the United States](https://specstream.ai/data/businesses/records-storage-companies/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
- [Bags luggage companies in the United States](https://specstream.ai/data/businesses/bags-luggage-companies/united-states)
- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
